298 related articles for article (PubMed ID: 35190177)
21. First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial.
Paz-Ares L; Ciuleanu TE; Cobo M; Schenker M; Zurawski B; Menezes J; Richardet E; Bennouna J; Felip E; Juan-Vidal O; Alexandru A; Sakai H; Lingua A; Salman P; Souquet PJ; De Marchi P; Martin C; Pérol M; Scherpereel A; Lu S; John T; Carbone DP; Meadows-Shropshire S; Agrawal S; Oukessou A; Yan J; Reck M
Lancet Oncol; 2021 Feb; 22(2):198-211. PubMed ID: 33476593
[TBL] [Abstract][Full Text] [Related]
22. Neoadjuvant nivolumab plus chemotherapy in resectable non-small-cell lung cancer in Japanese patients from CheckMate 816.
Mitsudomi T; Ito H; Okada M; Sugawara S; Shio Y; Tomii K; Okami J; Sakakura N; Kubota K; Takamochi K; Atagi S; Tsuboi M; Oizumi S; Ikeda N; Ohde Y; Ntambwe I; Mahmood J; Cai J; Tanaka F
Cancer Sci; 2024 Feb; 115(2):540-554. PubMed ID: 38098261
[TBL] [Abstract][Full Text] [Related]
23. Neoadjuvant atezolizumab and chemotherapy in patients with resectable non-small-cell lung cancer: an open-label, multicentre, single-arm, phase 2 trial.
Shu CA; Gainor JF; Awad MM; Chiuzan C; Grigg CM; Pabani A; Garofano RF; Stoopler MB; Cheng SK; White A; Lanuti M; D'Ovidio F; Bacchetta M; Sonett JR; Saqi A; Rizvi NA
Lancet Oncol; 2020 Jun; 21(6):786-795. PubMed ID: 32386568
[TBL] [Abstract][Full Text] [Related]
24. Prospective trial of immuno(chemo)therapy before resection, definitive chemoradiotherapy or palliative therapy in patients with locally advanced or oligometastatic non-small cell lung cancer without a primary curative option.
Faehling M; Fallscheer S; Kramberg S; Sträter J; Eschmann S; Sätzler R; Heinzelmann F
Eur J Cancer; 2021 Oct; 156():175-186. PubMed ID: 34461420
[TBL] [Abstract][Full Text] [Related]
25. First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 4-Year Outcomes From the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 Trial.
Paz-Ares LG; Ramalingam SS; Ciuleanu TE; Lee JS; Urban L; Caro RB; Park K; Sakai H; Ohe Y; Nishio M; Audigier-Valette C; Burgers JA; Pluzanski A; Sangha R; Gallardo C; Takeda M; Linardou H; Lupinacci L; Lee KH; Caserta C; Provencio M; Carcereny E; Otterson GA; Schenker M; Zurawski B; Alexandru A; Vergnenegre A; Raimbourg J; Feeney K; Kim SW; Borghaei H; O'Byrne KJ; Hellmann MD; Memaj A; Nathan FE; Bushong J; Tran P; Brahmer JR; Reck M
J Thorac Oncol; 2022 Feb; 17(2):289-308. PubMed ID: 34648948
[TBL] [Abstract][Full Text] [Related]
26. Surgical perspective in neoadjuvant chemoimmunotherapy for stage II-III non-small cell lung cancer.
Hong T; Sun T; Zhang M; Liu X; Yuan Y; Dolo PR; Chen B; Zhang H
Thorac Cancer; 2021 Oct; 12(20):2796-2802. PubMed ID: 34463034
[TBL] [Abstract][Full Text] [Related]
27. Comparison of mediastinal lymph node status and relapse pattern in clinical stage IIIA non-small cell lung cancer patients treated with neoadjuvant chemotherapy versus upfront surgery: A single center experience.
Savic M; Kontic M; Ercegovac M; Stojsic J; Bascarevic S; Moskovljevic D; Kostic M; Vesovic R; Popevic S; Laban M; Markovic J; Jovanovic D
Thorac Cancer; 2017 Sep; 8(5):393-401. PubMed ID: 28671758
[TBL] [Abstract][Full Text] [Related]
28. Pharmacodynamics of Pre-Operative PD1 checkpoint blockade and receptor activator of NFkB ligand (RANKL) inhibition in non-small cell lung cancer (NSCLC): study protocol for a multicentre, open-label, phase 1B/2, translational trial (POPCORN).
Ahern E; Cubitt A; Ballard E; Teng MWL; Dougall WC; Smyth MJ; Godbolt D; Naidoo R; Goldrick A; Hughes BGM
Trials; 2019 Dec; 20(1):753. PubMed ID: 31856909
[TBL] [Abstract][Full Text] [Related]
29. Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer.
Hellmann MD; Paz-Ares L; Bernabe Caro R; Zurawski B; Kim SW; Carcereny Costa E; Park K; Alexandru A; Lupinacci L; de la Mora Jimenez E; Sakai H; Albert I; Vergnenegre A; Peters S; Syrigos K; Barlesi F; Reck M; Borghaei H; Brahmer JR; O'Byrne KJ; Geese WJ; Bhagavatheeswaran P; Rabindran SK; Kasinathan RS; Nathan FE; Ramalingam SS
N Engl J Med; 2019 Nov; 381(21):2020-2031. PubMed ID: 31562796
[TBL] [Abstract][Full Text] [Related]
30. Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trial.
Rozeman EA; Menzies AM; van Akkooi ACJ; Adhikari C; Bierman C; van de Wiel BA; Scolyer RA; Krijgsman O; Sikorska K; Eriksson H; Broeks A; van Thienen JV; Guminski AD; Acosta AT; Ter Meulen S; Koenen AM; Bosch LJW; Shannon K; Pronk LM; Gonzalez M; Ch'ng S; Grijpink-Ongering LG; Stretch J; Heijmink S; van Tinteren H; Haanen JBAG; Nieweg OE; Klop WMC; Zuur CL; Saw RPM; van Houdt WJ; Peeper DS; Spillane AJ; Hansson J; Schumacher TN; Long GV; Blank CU
Lancet Oncol; 2019 Jul; 20(7):948-960. PubMed ID: 31160251
[TBL] [Abstract][Full Text] [Related]
31. Dose-Limiting Pulmonary Toxicity in a Phase 1/2 Study of Radiation and Chemotherapy with Ipilimumab Followed by Nivolumab for Patients With Stage 3 Unresectable Non-Small Cell Lung Cancer.
Liveringhouse CL; Latifi K; Asous AG; Lam NB; Rosenberg SA; Dilling TJ; MacMillan GV; Chiappori AA; Haura EB; Creelan B; Gray JE; Tanvetyanon T; Shafique MR; Saltos AN; Weiner AA; Clarke J; Kelsey CR; Kim S; Caudell JJ; Rose TA; Conejo-Garcia JR; Li J; Schell MJ; Antonia SJ; Perez BA
Int J Radiat Oncol Biol Phys; 2023 Jul; 116(4):837-848. PubMed ID: 36657497
[TBL] [Abstract][Full Text] [Related]
32. [Application of Neoadjuvant Immuno-chemotherapy in NSCLC].
Chen S; Zhao Z; Long H
Zhongguo Fei Ai Za Zhi; 2021 Apr; 24(4):284-292. PubMed ID: 33910277
[TBL] [Abstract][Full Text] [Related]
33. First-line nivolumab plus ipilimumab with or without chemotherapy for Japanese patients with non-small cell lung cancer: LIGHT-NING study.
Imai H; Kijima T; Azuma K; Kishi K; Saito H; Yamaguchi T; Tanizaki J; Yoneshima Y; Fujita K; Watanabe S; Kitazono S; Fukuhara T; Hataji O; Toi Y; Mizutani H; Hamakawa Y; Maemondo M; Ohsugi T; Suzuki K; Horinouchi H; Ohe Y
Jpn J Clin Oncol; 2024 Apr; 54(4):452-462. PubMed ID: 38271158
[TBL] [Abstract][Full Text] [Related]
34. Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden.
Hellmann MD; Ciuleanu TE; Pluzanski A; Lee JS; Otterson GA; Audigier-Valette C; Minenza E; Linardou H; Burgers S; Salman P; Borghaei H; Ramalingam SS; Brahmer J; Reck M; O'Byrne KJ; Geese WJ; Green G; Chang H; Szustakowski J; Bhagavatheeswaran P; Healey D; Fu Y; Nathan F; Paz-Ares L
N Engl J Med; 2018 May; 378(22):2093-2104. PubMed ID: 29658845
[TBL] [Abstract][Full Text] [Related]
35. Survival update of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma in the OpACIN and OpACIN-neo trials.
Versluis JM; Menzies AM; Sikorska K; Rozeman EA; Saw RPM; van Houdt WJ; Eriksson H; Klop WMC; Ch'ng S; van Thienen JV; Mallo H; Gonzalez M; Torres Acosta A; Grijpink-Ongering LG; van der Wal A; Bruining A; van de Wiel BA; Scolyer RA; Haanen JBAG; Schumacher TN; van Akkooi ACJ; Long GV; Blank CU
Ann Oncol; 2023 Apr; 34(4):420-430. PubMed ID: 36681299
[TBL] [Abstract][Full Text] [Related]
36. Neoadjuvant Ipilimumab + Nivolumab + Chemotherapy Enhances Pathologic Responses.
Cancer Discov; 2023 Jun; 13(6):OF11. PubMed ID: 36999975
[TBL] [Abstract][Full Text] [Related]
37. PRIME-HCC: phase Ib study of neoadjuvant ipilimumab and nivolumab prior to liver resection for hepatocellular carcinoma.
Pinato DJ; Cortellini A; Sukumaran A; Cole T; Pai M; Habib N; Spalding D; Sodergren MH; Martinez M; Dhillon T; Tait P; Thomas R; Ward C; Kocher H; Yip V; Slater S; Sharma R
BMC Cancer; 2021 Mar; 21(1):301. PubMed ID: 33757459
[TBL] [Abstract][Full Text] [Related]
38. Pulmonary resection after curative intent radiotherapy (>59 Gy) and concurrent chemotherapy in non-small-cell lung cancer.
Sonett JR; Suntharalingam M; Edelman MJ; Patel AB; Gamliel Z; Doyle A; Hausner P; Krasna M
Ann Thorac Surg; 2004 Oct; 78(4):1200-5; discussion 1206. PubMed ID: 15464470
[TBL] [Abstract][Full Text] [Related]
39. Perioperative Nivolumab and Chemotherapy in Stage III Non-Small-Cell Lung Cancer.
Provencio M; Nadal E; González-Larriba JL; Martínez-Martí A; Bernabé R; Bosch-Barrera J; Casal-Rubio J; Calvo V; Insa A; Ponce S; Reguart N; de Castro J; Mosquera J; Cobo M; Aguilar A; López Vivanco G; Camps C; López-Castro R; Morán T; Barneto I; Rodríguez-Abreu D; Serna-Blasco R; Benítez R; Aguado de la Rosa C; Palmero R; Hernando-Trancho F; Martín-López J; Cruz-Bermúdez A; Massuti B; Romero A
N Engl J Med; 2023 Aug; 389(6):504-513. PubMed ID: 37379158
[TBL] [Abstract][Full Text] [Related]
40. Safety and Feasibility of Lung Resection After Immunotherapy for Metastatic or Unresectable Tumors.
Bott MJ; Cools-Lartigue J; Tan KS; Dycoco J; Bains MS; Downey RJ; Huang J; Isbell JM; Molena D; Park BJ; Rusch VW; Sihag S; Jones DR; Adusumilli PS
Ann Thorac Surg; 2018 Jul; 106(1):178-183. PubMed ID: 29550207
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]